What approval means—and does not mean.

A product travels through several questions

Medicine development can move from laboratory and other nonclinical work into studies in people, regulatory review and monitoring after marketing. Many candidates do not reach the market: questions about safety, effectiveness, manufacturing or commercial feasibility may remain unresolved. Later studies generally add information about effectiveness and less common harms, but no study programme can observe every possible outcome.

An application concerns a specific product, not just an ingredient. Review may cover its proposed use, dose, how it is taken, manufacturing, clinical evidence, label and instructions for safe use. A trial registration, promising mechanism, patent, company announcement or headline does not itself give permission to market it.12

Attach the decision to its scope

Check the exact product and active ingredient, approved use, people it is for, form, dose, country and decision date. “Approved” without those details can suggest more than a regulator decided. US FDA approval and EU marketing authorisation are decisions in different systems; one does not automatically establish the other.

A product can be approved for one disease and studied for another. Its approved use can be limited by age, prior treatment, disease severity, a biomarker, dose or other required care. Read the current label or product information for its conditions, warnings and exclusions.23

A study is not an authorisation

Permission to study a treatment is not general permission to market it. Evidence for one condition does not prove benefit for every proposed use. A trial protocol, application to investigate a product, accelerated-development designation and published result are different from a marketing decision.

A familiar ingredient can also appear in an unapproved form, supplement, compounded product or research-only setting. The same chemical name does not establish the same quality, dose, manufacturing controls, evidence or legal status. This website does not provide individual prescribing advice or a country-by-country legal database.42

Emergency use is a separate status

In the United States, an Emergency Use Authorization (EUA) can permit an unapproved product, or an unapproved use of an approved product, during a qualifying emergency when legal conditions are met. The FDA describes a different evidence standard from approval: it may conclude that a product may be effective and that its known and potential benefits outweigh its known and potential risks, based on the information available.

An EUA is not the same as approval or licensure. It can be revised or revoked as evidence and emergency conditions change. Check the status of the exact product, use and country.52

What reviewers are deciding

Regulators weigh the benefits and risks for the proposed use. They consider whether evidence supports the benefit, what is known about safety, whether the product can be made consistently and whether its label explains limitations, warnings and monitoring. The European Medicines Agency describes a positive benefit–risk balance for the intended population as part of EU authorisation.

Approval does not remove every uncertainty. Trials can be short, selective or too small to reveal rare or delayed harms. Participants may be monitored more closely than people in routine care. Laboratory results do not always match outcomes that matter to patients. Approval is a decision about the evidence and conditions reviewed, not a promise of zero risk or benefit for everyone.23

Accelerated routes still have conditions

For serious conditions with unmet medical needs, the FDA can grant accelerated approval using a surrogate or intermediate clinical measure reasonably likely to predict a clinical benefit. The sponsor must conduct confirmatory studies. If the expected benefit is not verified, FDA procedures can lead to withdrawal, but removal is not automatic. Accelerated approval differs from Priority Review, Fast Track and Breakthrough Therapy designations.

In the EU, conditional marketing authorisation can use less comprehensive data when the benefit–risk balance is positive, other criteria are met and fuller data are expected. It lasts one year and can be renewed annually. It has specific obligations and can become a standard authorisation when they are met.

Authorisation under exceptional circumstances is different: it applies when comprehensive data cannot be obtained even after authorisation and normally does not become a standard authorisation. For either route, ask what evidence supported the decision, what obligations remain and which regulator made it.67101112

Approval does not end safety research

Monitoring continues because wider and longer use can reveal information that was missed before approval. FDA and EMA systems can include further studies and label updates, and, where law and evidence support them, restrictions, suspension or withdrawal. Procedures and powers differ by country.

A report after treatment is a signal to investigate, not automatic proof that treatment caused it. No signal does not prove a risk is impossible. In the EU, a black triangle marks medicines under additional monitoring. It encourages reporting and does not by itself mean a medicine is unsafe.289

Approval is not the same as access or recommendation

Authorisation permits marketing under specific conditions. It does not necessarily decide whether a health service, insurer or hospital will pay for the product, or whether a clinician will recommend it to a particular person. Those decisions also involve clinical needs, costs, local policy and individual circumstances. An authorised product may be unavailable in a location or subject to different access restrictions.32

A five-question status check

Which regulator, country and date does the claim refer to? Is it an authorisation for a product, a clinical study, a company claim or a research idea? What use, people, form, dose and duration does the decision cover? What benefits, harms, uncertainties and follow-up obligations were considered? Has newer evidence changed the label or status?

If these details are missing, the evidence may only show that a product is being studied or that a decision exists somewhere—not its exact scope.289